Generic drug
Teriflunomide price, strengths & recalls
Pharmacies pay $9.13 for 30 tablets of Teriflunomide 7 mg tablet this week, and from $6.70 to $9.13 across its 2 priced strengths and forms. 7 manufacturers make it. 1 recall is ongoing. Its official label last changed on April 9, 2026.
1 open recallGeneric- Fair cash price
- $21.00
- Strengths
- 2
- Makers
- 7
- Updated
- Nov 11
Teriflunomide price by strength
What pharmacies pay for each strength and form this week (Nov 11, 2026), for 30 tablets. Choose one for its fair price, 52-week chart and makers.
| Strength and form | Per unit | Pharmacies pay |
|---|---|---|
| 7 mg tablet | $0.3044 | $9.13 / 30 tablets |
| 14 mg tablet | $0.2234 | $6.70 / 30 tablets |
Supply status: shortages & recalls
Recalls
A recall names specific lots. Check the lot number on your package against the recall before you worry - and don't stop a medicine without asking your pharmacist. What to do if your medication is recalled.
What people paid for Teriflunomide
Bought it recently? Share the price, the pharmacy and how you paid - it's the most useful thing the next person can read.
Official label & what changed
These highlights do not include all the information needed to use TERIFLUNOMIDE TABLETS safely and effectively. See full prescribing information for TERIFLUNOMIDE TABLETS. TERIFLUNOMIDE tablets, for oral use Initial U.S. Approval: 2012
WARNING: HEPATOTOXICITY and EMBRYOFETAL TOXICITY
• Hepatotoxicity
Clinically significant and potentially life-threatening liver injury, including acute liver failure requiring transplant, has been reported in patients treated with teriflunomide in the postmarketing setting [see Warnings and Precautions (5.1)]. Concomitant use of teriflunomide with other hepatotoxic drugs may increase the risk of severe liver injury.
Obtain transaminase and bilirubin levels within 6 months before initiation of teriflunomide therapy. Monitor ALT levels at least monthly for six months after starting teriflunomide [see Warnings and Precautions (5.1)]. If drug induced liver injury is suspected, discontinue teriflunomide and start an accelerated elimination procedure with cholestyramine or charcoal [see Warnings and Precautions (5.3)]. Teriflunomide is contraindicated in patients with severe hepatic impairment [see Contraindications (4)]. Patients with pre-existing liver disease may be at increased risk of developing elevated serum transaminases when taking teriflunomide.
• Embryofetal Toxicity
Teriflunomide is contraindicated for use in pregnant women and in females of reproductive potential who are not using effective contraception because of the potential for fetal harm. Teratogenicity and embryolethality occurred in animals at plasma teriflunomide exposures lower than that in humans. Exclude pregnancy before the start of treatment with teriflunomide in females of reproductive potential. Advise females of reproductive potential to use effective contraception during teriflunomide treatment and during an accelerated drug elimination procedure after teriflunomide treatment. Stop teriflunomide and use an accelerated drug elimination procedure if the patient becomes pregnant [see Contraindications (4), Warnings and Precautions (5.2, 5.3), Use in Specific Populations (8.1, 8.3), and Clinical Pharmacology (12.3)].
WARNING: HEPATOTOXICITY and EMBRYOFETAL TOXICITY
See full prescribing information for complete boxed warning.
• Hepatotoxicity
Clinically significant and potentially life-threatening liver injury, including acute liver failure requiring transplant, has been reported in patients treated with teriflunomide in the postmarketing setting (5.1). Concomitant use of teriflunomide with other hepatotoxic drugs may increase the risk of severe liver injury. Obtain transaminase and bilirubin levels within 6 months before initiation of teriflunomide and monitor ALT levels at least monthly for six months (5.1). If drug induced liver injury is suspected, discontinue teriflunomide and start accelerated elimination procedure (5.3).
• Embryofetal Toxicity
Teratogenicity and embryolethality occurred in animals administered teriflunomide (5.2, 8.1). Exclude pregnancy prior to initiating teriflunomide therapy (4, 5.2, 8.1, 8.3). Advise use of effective contraception in females of reproductive potential during treatment and during an accelerated drug elimination procedure (4, 5.2, 5.3, 8.1, 8.3). Stop teriflunomide and use an accelerated drug elimination procedure if the patient becomes pregnant (5.2, 5.3, 8.1).
Recent major changes (as listed on the label)
Warnings and Precautions (5.8) 2/2026
We check this label every day. When it changes, the sections that changed appear here, old text beside new.
We show the official text and what changed; we don't interpret it. Ask your pharmacist or prescriber what a change means for you.
Approval, patents & generics
- Generic makers
- 7 approved generic applications on the market
Teriflunomide questions
How much does teriflunomide cost without insurance?
Pharmacies pay about $9.13 for 30 tablets of teriflunomide 7 mg tablet ($0.3044 per tablet). A fair cash price - that cost plus a 15% margin and a typical dispensing fee - is about $21.00. If you're quoted much more, check your quote and ask for the pharmacy's cash price.
Is teriflunomide in shortage?
No shortage is reported for teriflunomide right now. We check the national shortage list every day.
Has teriflunomide been recalled?
1 recall on record, 1 ongoing. Recalls name specific lots - check yours.
When did the teriflunomide label last change?
The official label was last updated on April 9, 2026 (version 7). See what changed.
Talk about teriflunomide
No comments yet. Questions, tips, what worked for you - start the conversation.